Company news
Rigel Pharmaceuticals, Inc. news in 2023
Rigel Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
December 7, 2023
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
November 6, 2023
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
November 1, 2023
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
October 30, 2023
Rigel Announces Presentation at the Upcoming IDWeek 2023
October 10, 2023
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
July 31, 2023
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
July 24, 2023
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
June 6, 2023
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
June 5, 2023
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
May 31, 2023
Rigel to Present at the Jefferies 2023 Global Healthcare Conference
May 30, 2023
Rigel Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023
Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
April 24, 2023
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 6, 2023
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
February 27, 2023
Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
February 1, 2023
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
January 17, 2023
Rigel Pharmaceuticals Provides Business Update
January 8, 2023
Calls in 2023
Decks in 2023
- Q3 2023 Earnings Presentation
Earnings · 30 slides · Nov 7, 2023